Wednesday, October 30, 2013
• Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., provided an update on the status of its Phase III trial with lead candidate Firdapse (amifampridine phosphase) for the treatment of Lambert-Eaton myasthenic syndrome.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.